12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Mepolizumab: Phase III started

GlaxoSmithKline began the 32-week double-blind, placebo-controlled, international Phase III MEA115588 trial to evaluate 75 mg IV mepolizumab and 100 mg subcutaneous mepolizumab every 4 weeks for...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >